(CercleFinance.com) – Merck announces that the United States Food and Drug Administration (FDA) has validated the administration by intramuscular (IM) injection of Merck’s MMRV family vaccines (MMR®II, VARIVAX® and ProQuad® ) previously only administered by subcutaneous (SC) injection.
‘We are proud to introduce an alternate delivery method for the MMR®II, VARIVAX® and ProQuad® vaccines, which have played an important role in the fight against measles, mumps, rubella, and varicella in the United States. States,” said Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories.
With these approvals, healthcare professionals now have the flexibility to choose to administer all injectable pediatric vaccines via the same intramuscular route.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
